In January of this year, the U.S. Food and Drug Administration approved a drug that combines the brain and spinal cord in a way that doctors say is able to treat symptoms of vertigo.
The new drug, named Integrative Nerve Management (INM), is based on a molecule developed by the University of Michigan that can boost the function of nerve cells and stimulate the production of nerve growth factor (NGF).
It works by stimulating a specific gene in the spinal cord that helps to control the growth of nerve fibres.
Nerve growth factor is a substance found in certain bacteria that helps support nerve growth and strength.
The brain is a complex organ that can control how the nerve cells communicate, but scientists believe the brain doesn’t control the amount of nerve cell growth or strength.
The team of scientists who developed INM, led by the researchers at the University, are now working to determine how the new drug will affect nerve cells in the brain.
“This drug has been around for a while,” said Dr. Richard Harkness, professor of neurosurgery at the university.
“We think it’s really exciting because it allows us to take a molecule that works well in humans and actually manipulate it in animals, so that the drug affects the brain in ways that aren’t known to be possible in humans.
There are a lot of drugs in the pipeline that are really, really promising.
But in terms of the efficacy of the drugs in humans, we’re pretty excited about this drug.”
According to the researchers, INM is able of “boosting the production and function of a subset of nerve fibers.”
“In humans, the normal rate of nerve activity is about 20-30 percent,” Dr. Harkess said.
“The higher the nerve activity, the more the brain responds.
That’s a pretty robust response, and we’ve found that we can actually increase the activity of a group of nerve endings called the trigeminal nerve endings, which are associated with vision and touch.
In this particular study, the drug was shown to have a beneficial effect on trigeminals and other sensory and motor systems.”
The scientists plan to continue to study the effect of INM in humans for the next two years.
As a side benefit, Dr. Driscoll said, INm is “pretty safe” because it’s being developed by a company that has been in business for about 20 years.
“In this trial, the level of activity in the animals was pretty good.
There was no side effect,” he said.
However, Driscol said that it’s important to note that INM was used for “longer-term clinical trials” that will likely take a longer time to complete.
It’s also important to keep in mind that the effects of the drug are not permanent.
So if you experience vertigo symptoms for a few days, Dr Harkiss recommends taking the drug for a month to see if it helps you fall back into a normal life.